Cilengitide (EMD121974) suppresses tumor growth of head and neck squamous cell carcinoma ex vivo

Gunnar Wichmann, Daphne Schlegel, Susan Cedra, Andreas Dietz, Christian Mozet, Anett Reiche, Kristin Herrmann, Nadine Weissheimer & Andreas Boehm
Introduction: Cilengitide (Cil), an inhibitor of integrins αvβ3 and αvβ5, is under investigation in clinical trials in head and neck squamous cell carcinoma (HNSCC). However, combinatory effects of Cil with Erbitux (E) on colony-formation (CF) of HNSCC on various extracellular[for full text, please go to the a.m. URL]